Amgen (AMGN) Osake Kurssi

Amgen Inc is primarily active in the biotechnology industry.

The main competitors of Amgen Inc in the market are Johnson & Johnson, Novartis AG, Pfizer Inc, and Roche Holding AG.

Amgen Inc. is a biotechnology company that was founded in 1980. It has its headquarters in Thousand Oaks, California. The company specializes in developing and manufacturing human therapeutics. Amgen Inc. has a rich history of groundbreaking innovations and advancements in the field of biotechnology. It has introduced numerous successful drugs and therapies, including Epogen, Neupogen, and Enbrel, which have had a significant impact on the treatment of various diseases. Amgen Inc. has grown into one of the largest biotechnology companies globally and continues to strive for advancements in medical science to improve patients' lives.

Amgen Inc has achieved several significant milestones throughout its history. It pioneered the development and commercialization of biotechnology-based medicines, leading to groundbreaking treatments for various diseases. Notably, Amgen's introduction of Epogen revolutionized the treatment of anemia in patients with chronic kidney disease. The company also played a crucial role in advancing the science of targeted therapies with the launch of drugs like Neulasta and Neupogen, enhancing cancer patient care. Additionally, Amgen has expanded its portfolio with innovative drugs addressing osteoporosis, psoriasis, and migraine prevention. Through continuous research and advancements, Amgen Inc remains at the forefront of biopharmaceutical innovation.

Amgen Inc is primarily present in the United States, with its headquarters located in Thousand Oaks, California. The company also has a significant presence in various other countries and regions including Europe, Canada, Japan, and Australia. With a global reach, Amgen Inc operates in many key markets worldwide, leveraging its expertise and innovative portfolio of biopharmaceutical products to improve patients' lives.

Amgen Inc represents values such as integrity, excellence, and a commitment to patients. The corporate philosophy of Amgen focuses on innovative science, delivering life-changing medicines, and addressing unmet medical needs. Amgen aims to improve the health and well-being of individuals worldwide through their cutting-edge research and development efforts. With a strong emphasis on scientific rigor, ethical practices, and patient-centered approach, Amgen is dedicated to pioneering breakthrough therapies to advance medical care and make a positive impact on society.

Analyytikot asettavat tällä hetkellä Amgen-osakkeelle keskimääräisen tavoitehinnan 379,11 USD (mediaani: 384,00 USD), mikä merkitsee −1,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 43 analyytikkoarvioon.

Amgen Analyytikkojen kursstavoitteet 2026

43 analyytikkoa arvioi tällä hetkellä Amgen-osaketta: 20 suosittaa ostoa, 20 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Amgen-yhtiöltä 38,96 Mrd. USD liikevaihtoa ja 23,03 USD osakekohtaista tulosta.

Amgen Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Amgen-osake noteerataan hintaan 336,01 EUR (385,65 USD).

Amgen-osake (AMGN) on listattuna 10 pörssissä, muun muassa: NASDAQ (AMGN), London (0R0T.L), SIX (Zürich) (AMGN.SW), XETRA (AMG.DE), Frankfurt (AMG.F), München (AMG.MU), Düsseldorf (AMG.DU), Hamburg (AMG.HM).

Amgen Inc. is a biotechnology company that focuses on the development, manufacturing, and marketing of biopharmaceuticals. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is a key player in the biotechnology field with over 21,000 employees worldwide. Amgen has several divisions, including oncology, hematology, nephrology, bone metabolism, and inflammation. In oncology, Amgen offers various drugs for the treatment of cancer, including Blincyto, Vectibix, and Neulasta. In hematology, the company has developed Aranesp and Epogen for the treatment of anemia. Additionally, Amgen also offers various products for the treatment of kidney diseases such as Sensipar and Parsabiv. In the field of bone metabolism, Amgen provides medications for the treatment of osteoporosis, such as Prolia and Xgeva. In the field of inflammation, Amgen has developed Enbrel for the treatment of rheumatoid arthritis and other inflammatory diseases. Amgen also holds a significant position in the biosimilars market. Biosimilars are imitations of biological drugs that are already on the market. They allow patients to access more affordable treatment options while still providing the same effectiveness and safety as the original product. Amgen has several biosimilars on the market, including Amgevita and Mvasi. Amgen's business model is based on the development of new biopharmaceuticals and biosimilars. The company invests significant financial resources in research and development to create innovative products that aim to improve the health and well-being of patients. Amgen also collaborates closely with other companies and research institutions to find creative solutions for medical challenges. To implement its business model, Amgen has built a global network of production and distribution centers to distribute its products worldwide. The company also has a team of disease-fighting experts, as well as researchers and engineers who work closely together to develop and improve new products. Overall, Amgen has a strong business model based on the development of biopharmaceuticals and biosimilars. The company produces high-quality products to enhance the health of patients worldwide. With a dedicated team of professionals focusing on research, development, and disease-fighting, Amgen is well-positioned to continue creating innovative solutions for medical challenges and expanding its market share.

odotettu liikevaihto Amgen on 38,96 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Amgen on 12,51 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Amgen:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,74. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Amgen-osakkeen arvostusta.

Amgen:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,38. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Amgen-osakkeen arvostuskennuslukuna.

Amgen:n Eulpool-laatuscore on 6/10.

Amgen:n ISIN on US0311621009. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Amgen:n WKN on 867900. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Amgen:n ticker on AMGN. Tämä pörssinoteeraus käytetään Amgen-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Amgen maksoi osinkoa 9,52 USD . Tämä vastaa osingontuottoa noin 2,47 %. Tulevien 12 kuukauden aikana Amgen odotetaan maksavan osinkoa 10,89 USD.

Amgen:n nykyinen osinkotuotto on 2,47 %.

Amgen maksaa osinkoa, joka jaetaan kuukausina marraskuu, helmikuu, toukokuu, elokuu.

Amgen maksoi osinkoa joka vuosi viimeisten 15 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 10,89 USD. Tämä vastaa osingontuottoa 2,90 %.

Amgen kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Amgen:sta päivältä 11.9.2026 määrässä 2,52 USD, sinulla piti olla osake portfoliossasi ennen irtoamispäivää 21.8.2026.

Viimeinen osinko maksettiin 11.9.2026.

Vuonna 2025 Amgen jakoi 9,52 USD osinkona.

Amgen:n osingot jaetaan valuutassa USD.